Halberd Corp (HALB)

[EHRjunkie]

This is about the first project HALB and ASU are working on. Realizing these goals will result in 3 new granted US patents, that are provisional at the moment.


Jackson Center, PA, September 14, 2020 –

Halberd Corporation (OTC PINK: “HALB“) today released the specifics of the initial phase of the $1.4 Million seven-phase research project with Arizona State University.

The University project for a rapid test to identify Covid-19 infection, from a sample such as saliva, mucus, blood and CSF will be based upon the following two provisional patent applications:

Method for Treating and Curing Covid-19 Infection, and
Method for the Rapid Identification of Covid-19 Infection.

The initial phase will be the creation of a unique Covid-19 fluorescent antibody which may also contain an albumin moiety and targets the rapid identification of the Covid-19 target antigens. The use of fluorescent antibodies has a two-fold purpose – rapid identification of the presence of Covid-19 in a fluid sample, and targeting for removal through extracorporeal means, including possible laser ablation, as disclosed in our two issued patents and three provisional patent applications.

HALB's website has been updated again, the ASU contract is on the home page:
https://halberdcorporation.com/

https://halberdcorporation.com/wp-content/uploads/2020/09/ASU-K-Fully-Executed.pdf